Our Annual Report

We are a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realise the potential of what science can do. In our Annual Report we report on the progress we made in 2021 in pushing the boundaries of science to deliver life-changing medicines.


01

Chair & CEO





02

Strategic overview

We are a global pharmaceutical business with a science-led and patient-focused value proposition committed to excellence in the research, development and commercialisation of prescription medicines.

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.


Accelerate Innovative Science


Accelerating the next wave of new molecular entities, building our capabilities in immunology and rare diseases, pursuing new scientific modalities and driving R&D productivity.


Pipeline progression events

321 

(2020: 36)

1. 26 against our Group scorecard for determining annual bonus. 2021 total includes Alexion.

2. 25 against our Group scorecard for determining annual bonus.

3. 17 against our Group scorecard for determining annual bonus.


Regulatory events

491 

(2020:53)

1. 37 against our Group scorecard for determining annual bonus. 2021 total includes Alexion.

2. 43 against our Group scorecard for determining annual bonus.

3. 37 against our Group scorecard for determining annual bonus.





Deliver Growth and Therapy Area Leadership


Meeting our growth and profitability goals through successful innovation and commercial excellence, as well as completing the Alexion acquisition.


Total revenue*

$37,417m 

(2020:$26,617m)

*Total Revenue consists of Product Sales and Collaboration Revenue.





Be a Great Place to Work


Contributing to the enterprise and to society, with a focus on inclusion and diversity, lifelong learning, improving access to healthcare, environmental protection, and ethics and transparency, as well as delivering our Ambition Zero Carbon programme.


Employee belief that AstraZeneca is a great place to work1

85% 

(2020:89%)

1. Source: November Pulse survey for each year.


Sustainability scorecard performance2
 

83% 

(2020: 93%)

2. A Green rating = more than 70% of our categories are rated green. Each category consists of several KPIs. We have 14 priority goals. Achievement of <9 is Red; 9 or 10 is Amber; 11 or 12 is Green; and 13 or 14 is Blue.


• Used for remuneration of Executive Directors

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.



03

Disease Area Review

We have a diversified portfolio with broad coverage across primary, specialty care and rare disease.



04

Sustainability Highlights

Our ambition is to harness the power of science and innovation in ways that have a positive impact on society, patients, healthcare systems and the environment, through actions for the long term.

Through our flagship $1 billion Ambition Zero Carbon programme, we are on track to reduce greenhouse gas emissions from our global operations by 98% by 2026 and halve our entire value chain footprint by 2030, on the way to a 90% reduction by 2045.



Access to healthcare

We are working towards a future where everyone can have access to sustainable health solutions for life-changing treatment and care.


Achievements in 2021:

31.0m

Over 199,000 healthcare workers and others trained since 2010 and over 31 million people reached through Access to Healthcare programmes.


Environmental protection

We aim to demonstrate global leadership by minimising our environmental impact across all our activities and products. Becoming increasingly circular, we are designing out waste and pollution, keeping products and materials in use, and maximising resource efficiency.


Achievements in 2021:

59%

59% reduction in Scope 1 and 2 greenhouse gas emissions since 2015.


Ethics and transparency

We seek to create positive societal impact and embed ethical behaviour in all our business activities, markets and value chain. We do this by promoting ethical, transparent and inclusive policies within our company as well as across all our partners and suppliers.


Achievements in 2021:

48.1%

48.1% of senior middle management roles and above are held by women.



05

Achieve Group Financial Targets

Cash generation is a key driver of long-term shareholder returns and facilitates reinvestment in our pipeline, which is critical for delivering new medicines and future value.


Net cash flow from operating activities

$6.0bn 

Up 24% at actual rate of exchange to $6.0bn


Reported EPS

$0.08

Down 97% at actual rate of exchange to $0.08
(down 84% at CER)


Core EPS

$5.29 

Up 32% at actual rate of exchange to $5.29
(up 37% at CER)


• Used for remuneration of Executive Directors

// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.